These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 12171725

  • 1. CAMPATH-1H in the treatment of autoimmune cytopenias.
    Marsh JC, Gordon-Smith EC.
    Cytotherapy; 2001; 3(3):189-95. PubMed ID: 12171725
    [Abstract] [Full Text] [Related]

  • 2. The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
    Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC.
    Br J Haematol; 2001 Sep; 114(4):891-8. PubMed ID: 11564082
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H.
    Rodon P, Breton P, Courouble G.
    Eur J Haematol; 2003 May; 70(5):319-21. PubMed ID: 12694169
    [Abstract] [Full Text] [Related]

  • 5. Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis.
    Reiff A, Shaham B, Weinberg KI, Crooks GM, Parkman R.
    J Clin Immunol; 2011 Aug; 31(4):615-22. PubMed ID: 21541793
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Monoclonal antibodies in the treatment of autoimmune cytopenias.
    Robak T.
    Eur J Haematol; 2004 Feb; 72(2):79-88. PubMed ID: 14962245
    [Abstract] [Full Text] [Related]

  • 8. CAMPATH-1 antibodies in stem-cell transplantation.
    Hale G, Cobbold S, Novitzky N, Bunjes D, Willemze R, Prentice HG, Milligan D, MacKinnon S, Waldmann H, CAMPATH Users.
    Cytotherapy; 2001 Feb; 3(3):145-64. PubMed ID: 12171722
    [Abstract] [Full Text] [Related]

  • 9. The CD52 antigen and development of the CAMPATH antibodies.
    Hale G.
    Cytotherapy; 2001 Feb; 3(3):137-43. PubMed ID: 12171721
    [No Abstract] [Full Text] [Related]

  • 10. Campath-1H therapy in refractory ocular inflammatory disease.
    Dick AD, Meyer P, James T, Forrester JV, Hale G, Waldmann H, Isaacs JD.
    Br J Ophthalmol; 2000 Jan; 84(1):107-9. PubMed ID: 10611109
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology.
    Dungarwalla M, Marsh JC, Tooze JA, Lucas G, Ouwehand W, Pettengell R, Dearden CE, Gordon Smith EC, Elebute MO.
    Ann Hematol; 2007 Mar; 86(3):191-7. PubMed ID: 17123083
    [Abstract] [Full Text] [Related]

  • 13. A personal history of the CAMPATH-1H antibody.
    Waldmann H.
    Med Oncol; 2002 Mar; 19 Suppl():S3-9. PubMed ID: 12180490
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Alemtuzumab therapy in B-cell lymphoproliferative disorders.
    Moreton P, Hillmen P.
    Semin Oncol; 2003 Aug; 30(4):493-501. PubMed ID: 12939718
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of CAMPATH-1H in BMT patients.
    Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G.
    Cytotherapy; 2001 Aug; 3(4):261-7. PubMed ID: 12171714
    [Abstract] [Full Text] [Related]

  • 18. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
    Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL.
    Clin Cancer Res; 2006 Dec 01; 12(23):7174-9. PubMed ID: 17145843
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.